Infinity Pharmaceuticals to Participate in B. Riley Securities Virtual Oncology Investor Conference
January 15 2021 - 8:35AM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate
in a Fireside Chat with Andrew D’Silva of B. Riley Securities on
Wednesday, January 20, 2021 at 10:30 am ET.
B. Riley is limiting the live audience to institutional
investors, investor relations, and employees of each presenting
company. Private investors will not be given access to the live
conference, but a replay will be available on the Events and
Presentations page of the Infinity Pharmaceuticals website
following the conference.
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to
developing novel medicines for people with cancer. Infinity is
advancing eganelisib, a first-in-class, oral immuno-oncology
development candidate that selectively inhibits PI3K-gamma, in
multiple clinical studies. MARIO-275 is a global, randomized,
placebo-controlled study of eganelisib combined with Opdivo® in I/O
naïve urothelial cancer. MARIO-3 is the first eganelisib
combination study in front-line advanced cancer patients and is
evaluating eganelisib in combination with Tecentriq® and Abraxane®
in front-line TNBC and in combination with Tecentriq and Avastin®
in front-line RCC. In collaboration with Arcus Biosciences,
Infinity is evaluating a checkpoint inhibitor-free, novel
combination regimen of eganelisib plus etrumadenant (dual adenosine
receptor antagonist) plus Doxil® in advanced TNBC patients. With
these studies Infinity is evaluating eganelisib in the anti-PD-1
refractory, I/O-naïve, and front-line and second line settings. For
more information on Infinity, please refer to Infinity's website at
www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc. Abraxane®
is a registered trademark of Abraxis BioScience, LLC. Avastin® is a
registered trademark of Genentech, Inc. Doxil® is a registered
trademark of Baxter Healthcare Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210115005108/en/
Ashley Robinson LifeSci Advisors, LLC 617-775-5956
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Apr 2023 to Apr 2024